Status:
UNKNOWN
To Determine the Efficacy of Neurokinin 1 Receptor Antagonist as a Therapeutic Tool Against Cytokine Storm and Respiratory Failure in Covid-19 Patients
Lead Sponsor:
Prof. Dr. Fridoon Jawad Ahmad
Collaborating Sponsors:
University of Lahore
Bahria International Hospital
Conditions:
Neurokinin 1 Receptor, Substance P, Respiratory Illness, Inflammation, Covid-19, Coronavirus
Eligibility:
All Genders
18-90 years
Phase:
PHASE3
Brief Summary
This is a randomized, randomized controlled trial to investigate the efficacy and safety of Neurokinin-1 Receptor (NK-1R) 80 mg orally given daily to treat cytokine storm causing inflammatory lung inj...
Detailed Description
Objective: To evaluate the clinical outcomes of Neurokinin 1 Receptor antagonist in Covid-19 patients against the usual treatments as controls Dosage Aprepitant capsules may be given to patients fro...
Eligibility Criteria
Inclusion
- Age \> 18 yrs
- Both genders
- Lab Confirmed COVID-19 infection by PCR or plasma positive of specific antibody against COVID-19
- In hospital treatment ≥ 72 hours
- Admitted patients
- Severe Disease (Respiratory rate \>=30/min; or (b) Rest SPO2\<=90%; or (c) PaO2/FiO2\<=300 mmHg) or
- Critical Phase (Respiratory failure and needs mechanical ventilation; or Shock occurs; or Multiple organ failure and needs ICU monitoring)
Exclusion
- Patients who are not willing to give consent
- known HIV,HBV, HCV infection
- pregnancy
Key Trial Info
Start Date :
June 15 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 30 2020
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04468646
Start Date
June 15 2020
End Date
August 30 2020
Last Update
July 13 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bahria International Hospital
Lahore, Punjab Province, Pakistan, 53720